Back to search
Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma trials you may qualify forBackground: Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in cancer-associated fibroblasts of certain cancer types. \[18F\]FAPI…
Background: \- Lung cancer is the leading cause of cancer-related death worldwide. It causes more than one million deaths every year. Researchers want to gathe…
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[212Pb\]Pb-MP0712, in patients aged ≥18 years with Sma…
The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic…
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacoki…
Background: Small cell lung cancer (SCLC) is the deadliest form of lung cancer. Extrapulmonary neuroendocrine cancer (EPNEC) is a similar type of cancer that d…
To test the safety of and effectiveness of XmAb20717 for participants with advanced rare cancers.
This is a first-in-human (FIH), open-label, Phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of ML261, an autologo…